Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaleads, a developer of small protease inhibiting molecules, has announced that its two Phase 1 studies for PL37 by oral route have demonstrated positive results.
Subscribe to our email newsletter
PL37 belongs to Dual ENKephalinase Inhibitors (DENKI), a class of painkillers, which targets peripheral pain, of neuropathic and osteoarthritic origin in particular, by oral route as well as central pain by IV route.
The two randomised, double-blind, placebo-controlled studies comprised 168 healthy volunteers, of which 126 received PL37 by oral route.
Both the studies demonstrated good safety and tolerability of PL37.
PL37 will thus enter into Phase 2 trials.